Hemophilia A Market Analysis, Epidemiology, Key Companies and Emerging Drugs

May 07 21:42 2020
Hemophilia A Market Analysis, Epidemiology, Key Companies and Emerging Drugs

Delveinsight Business Research
DelveInsight’s “Hemophilia A Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donated whole blood, subsequently by plasma and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A.

About 30% of severe hemophilia A patients develop neutralizing anti-FVIII alloantibodies (inhibitors), which render the FVIII replacement ineffective. The standard of care therapy for patients with inhibitors is to induce immune tolerance with high-dose, high-frequency FVIII and treatment with bypassing agents (e.g. recombinant activated factor VII such as NovoSeven, FEIBA).


Visit For Sample Pages: 



The Hemophilia A market report aslo covers emerging drugs, current treatment practices, Hemophilia A market share of the individual therapies, current and forecasted Hemophilia A Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Hemophilia A treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 


Hemophilia A Market Key Facts

  • Total diagnosed and treated prevalent population of Hemophilia A in the 7MM was assessed to be 38,212 in 2017.

  • According to DelveInsight’s analysis, the highest prevalent population of Hemophilia A is in the United States with 14,200 cases in 2017.

  • In the 7MM, approximately 30% of severe hemophilia A cases, i.e., 6,305 patients affected by inhibitors. In addition to this, 70% of the Hemophilia A cases were observed without inhibitors in 2017. The number of cases for both categories will increase during the study period.

  • Among the 7MM, the US accounts for 51% USD of the overall market size of hemophilia A in 2017.

  • Among the European 5 countries, the United Kingdom had the highest prevalent population of Hemophilia A, followed by France and Italy.



Key Benefits of Hemophilia A Market Report

  • Hemophilia A market report provides an in-depth analysis of Hemophilia A Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

  • The Hemophilia A market report will help in developing business strategies by understanding the Hemophilia A Market trends & developments, key players and future market competition that will shape and drive the Hemophilia A market in the upcoming years.

  • The Hemophilia A market report covers Hemophilia A current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Hemophilia A market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 


Hemophilia A Market

The Hemophilia A market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Hemophilia A market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Hemophilia A market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 


Hemophilia A Epidemiology

Hemophilia A is a general term for a group of rare bleeding disorders caused by a congenital deficiency of certain clotting factors. The main form of hemophilia is hemophilia A; it is different from Hemophilia B. The main difference between them is that Hemophilia B is associated with deficiency in factor IX (9) while Hemophilia A is associated with deficiency of factor VIII. More than 80% of people with hemophilia have hemophilia A.

 The Hemophilia A epidemiology section covers insights about historical and current Hemophilia A patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  


Hemophilia A Drugs Uptake and Key Market Players

The Hemophilia A Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemophilia A market or expected to get launched in the market during the study period. The analysis covers Hemophilia A market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The Key players in Hemophilia A market include such as

  • Biomarin Pharmaceutical

  • Novo Nordisk

  • Sanofi

  • Pfizer

  • Catalyst Biosciences

  • OPKO Biologics

  • Spark Therapeutics

  • Sangamo therapeutics

and others.


Table of Content

1. Key Insights

2. Executive Summary 

3. Hemophilia A Competitive Intelligence Analysis

4. Hemophilia A Market Overview at a Glance

5. Hemophilia A Disease Background and Overview

6. Hemophilia A Patient Journey

7. Hemophilia A Epidemiology and Patient Population

8. Hemophilia A Treatment Algorithm, Current Treatment, and Medical Practices

9. Hemophilia A Unmet Needs

10. Key Endpoints of Hemophilia A Treatment

11. Hemophilia A Marketed Products

12. Hemophilia A Emerging Therapies

13. Hemophilia A Seven Major Market Analysis

14. Attribute Analysis

15. Hemophilia A Market Outlook (7 major markets)

16. Hemophilia A Access and Reimbursement Overview

17. KOL Views on the Hemophilia A Market.

18. Hemophilia A Market Drivers

19. Hemophilia A Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer


About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.


Related Reports-

Hemophilia A Epidemiology Forecast to 2030

DelveInsight’s Hemophilia A Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hemophilia A in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


Hemophilia B Pipeline Insights, 2020

Hemophilia B Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hemophilia B market.


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/